Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor

Valentina Scabia, Ayyakkannu Ayyanan, Fabio Martino, Andrea Agnoletto, Laura Battista, Csaba Laszlo, Assia Treboux, Khalil Zaman, Athina Stravodimou, Didier Jallut, Maryse Fiche, Philip Bucher, Giovanna Ambrosini, George Sflomos and Cathrin Brisken ()
Additional contact information
Valentina Scabia: Ecole Polytechnique Fédérale de Lausanne
Ayyakkannu Ayyanan: Ecole Polytechnique Fédérale de Lausanne
Fabio Martino: Ecole Polytechnique Fédérale de Lausanne
Andrea Agnoletto: Ecole Polytechnique Fédérale de Lausanne
Laura Battista: Ecole Polytechnique Fédérale de Lausanne
Csaba Laszlo: Ecole Polytechnique Fédérale de Lausanne
Assia Treboux: Breast center, Lausanne University Hospital (CHUV)
Khalil Zaman: Breast center, Lausanne University Hospital (CHUV)
Athina Stravodimou: Breast center, Lausanne University Hospital (CHUV)
Didier Jallut: Réseau Lausannois du Sein
Maryse Fiche: International Cancer Prevention Institute
Philip Bucher: Ecole Polytechnique Fédérale de Lausanne
Giovanna Ambrosini: Ecole Polytechnique Fédérale de Lausanne
George Sflomos: Ecole Polytechnique Fédérale de Lausanne
Cathrin Brisken: Ecole Polytechnique Fédérale de Lausanne

Nature Communications, 2022, vol. 13, issue 1, 1-15

Abstract: Abstract Estrogen and progesterone receptor (ER, PR) signaling control breast development and impinge on breast carcinogenesis. ER is an established driver of ER + disease but the role of the PR, itself an ER target gene, is debated. We assess the issue in clinically relevant settings by a genetic approach and inject ER + breast cancer cell lines and patient-derived tumor cells to the milk ducts of immunocompromised mice. Such ER + xenografts were exposed to physiologically relevant levels of 17-β-estradiol (E2) and progesterone (P4). We find that independently both premenopausal E2 and P4 levels increase tumor growth and combined treatment enhances metastatic spread. The proliferative responses are patient-specific with MYC and androgen receptor (AR) signatures determining P4 response. PR is required for tumor growth in patient samples and sufficient to drive tumor growth and metastasis in ER signaling ablated tumor cells. Our findings suggest that endocrine therapy may need to be personalized, and that abrogating PR expression can be a therapeutic option.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-30898-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30898-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-30898-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().